The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 02, 2023

Filed:

Jan. 07, 2020
Applicant:

Alx Oncology Inc., South San Francisco, CA (US);

Inventors:

Jaume Pons, San Francisco, CA (US);

Laura Deming, Palo Alto, CA (US);

Corey Goodman, Marshall, CA (US);

Bang Janet Sim, Brisbane, CA (US);

Steven Elliot Kauder, San Mateo, CA (US);

Hong Wan, Foster City, CA (US);

Tracy Chia-Chien Kuo, San Mateo, CA (US);

Assignee:

ALX Oncology Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 47/68 (2017.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C07K 14/705 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70596 (2013.01); A61K 38/177 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6811 (2017.08); C07K 14/70503 (2013.01); C07K 16/00 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); A61K 38/00 (2013.01); A61K 38/1709 (2013.01); A61K 2039/505 (2013.01); C07K 14/4703 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein α (SIRP-α) D1 variant and (ii) an antibody.


Find Patent Forward Citations

Loading…